Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2019 | 1 |
2020 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
J Cancer Res Clin Oncol. 2020 May;146(5):1321-1334. doi: 10.1007/s00432-020-03167-0. Epub 2020 Mar 6.
J Cancer Res Clin Oncol. 2020.
PMID: 32144533
Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study.
Marques RP, Heudtlass P, Pais HL, Quintela A, Martins AP.
Marques RP, et al.
J Cancer Res Clin Oncol. 2019 Jul;145(7):1719-1728. doi: 10.1007/s00432-019-02924-0. Epub 2019 Apr 29.
J Cancer Res Clin Oncol. 2019.
PMID: 31037398
Item in Clipboard
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Marques RP, Duarte GS, Sterrantino C, Pais HL, Quintela A, Martins AP, Costa J.
Marques RP, et al.
Crit Rev Oncol Hematol. 2017 Oct;118:54-62. doi: 10.1016/j.critrevonc.2017.08.006. Epub 2017 Aug 25.
Crit Rev Oncol Hematol. 2017.
PMID: 28917269
Review.
Item in Clipboard
Cite
Cite